Psoriasis
Conditions
Interventions
Experimental Group:Weeks 1-4: Apply Fluticasone Propionate Cream once in the morning and Calcipotriol Ointment once in the evening. Weeks 5-8: Apply Calcipotriol Ointment twice daily from Monday to F
Control Group:Treated with Calcipotriol Ointment, twice daily. The treatment duration is 8 weeks.
Sponsors
Beijing Children's Hospital,Capital Medical University
Eligibility
Sex/Gender
All
Age
2 Years to 14 Years
Inclusion criteria
Inclusion criteria: 1. Children aged 2-14 years old, any gender. 2. Clinical diagnosis of plaque psoriasis, in stable condition, with affected Body Surface Area (BSA) <10% and PASI <10 (mild to moderate), with psoriasis primarily located on the limbs and trunk. 3. Patients and their parents voluntarily participate in this trial, sign an informed consent form, and agree to undergo treatment according to the protocol and timely visits during the trial.
Exclusion criteria
Exclusion criteria: 1. Patients with punctata, pustular, erythrodermic, or psoriatic arthritis psoriasis. 2. Patients with psoriasis in special areas such as the head, face, neck, genital area, perianal area, skin folds, etc. 3. Patients with localized psoriasis lesions accompanied by signs of bacterial, fungal, viral, or other pathogenic infections, or with exudation, ulceration, or erosion. 4. Patients with a known history of allergies to any component of the investigational drugs or drugs with similar chemical structures. 5. Patients with known contraindications to any of the investigational drugs. 6. Patients with severe diseases such as severe liver or kidney disease, cardiovascular disease, blood system disorders, autoimmune diseases, severe infections, diabetes, mental illness, or malignant tumors that may affect the correct evaluation of efficacy. 7. Patients who have received biologic therapy in the past 8 weeks; systemic medications (including but not limited to methotrexate, acitretin, cyclosporine), phototherapy (including but not limited to NB-UVB, PUVA), or traditional Chinese medicine treatment in the past 4 weeks; or topical medication treatment in the past 2 weeks (including but not limited to corticosteroids, vitamin D3 analogues, calcineurin inhibitors, salicylic acid, coal tar). 8. Patients who are unable to follow the planned follow-up schedule.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI 75 response rate at the end of treatment (week 8); | — |
Secondary
| Measure | Time frame |
|---|---|
| PASI 75 response rate at weeks 2 and 4 of the treatment period;PASI, sPGA, and CDLQI scores at baseline and at weeks 2, 4, and 8 of the treatment period;Treatment satisfaction rate among patients' parents at the end of treatment (week 8); | — |
Countries
China
Contacts
Public ContactZigang Xu
Beijing Children's Hospital,Capital Medical University
Outcome results
None listed